Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer

OncoImmunology

Volumn 6, Issue 3, 2017, Pages

  Li, Zhaoting ^a   Zhu, Yijia ^a   Li, Chenchen ^a   Trinh, Ryan ^b   Ren, Xueyan ^a   Sun, Fumou ^a   Wang, Youfu ^a   Shang, Pengzhao ^a   Wang, Tong ^a   Wang, Min ^a   Morrison, Sherie L ^b   Zhang, Juan ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD8+ T cells; colorectal cancer; DCs; IFN 2; tumor microenvironment; VEGFR2

Indexed keywords

ALPHA2A INTERFERON; HYBRID PROTEIN; JZA 00; JZA 01; LACTATE DEHYDROGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

AFFINITY CHROMATOGRAPHY; ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ACTIVATION; CELL CYCLE ARREST; CELL INVASION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; WESTERN BLOTTING;

EID: 85016598365     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1290038     Document Type: Article

References (42)

1. Spill F, Reynolds DS, Kamm RD, Zaman MH. Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol 2016; 40:41-8; PMID:26938687; http://dx.doi.org/10.1016/j.copbio.2016.02.007
2. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348(6230):74-80; PMID:25838376; http://dx.doi.org/10.1126/science.aaa6204
3. Pittet MJ. Behavior of immune players in the tumor microenvironment. Curr Opin Oncol 2009; 21(1):53-9; PMID:19125019; http://dx.doi.org/10.1097/CCO.0b013e32831bc38a
4. Buchbinder EI, McDermott DF. Interferon, interleukin-2, and other cytokines. Hematol Oncol Clin North Am 2014; 28(3):571-83; PMID:24880948; http://dx.doi.org/10.1016/j.hoc.2014.02.001
5. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50:past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6(12):975-90; PMID:18049472; http://dx.doi.org/10.1038/nrd2422
6. Farkas A, Kemeny L. Interferon-alpha in the generation of monocyte-derived dendritic cells:recent advances and implications for dermatology. Br J Dermatol 2011; 165(2):247-54; PMID:21410666; http://dx.doi.org/10.1111/j.1365-2133.2011.10301.x
7. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011; 208(10):2005-16; PMID:21930765; http://dx.doi.org/10.1084/jem.20101159
8. Paolini R, Bernardini G, Molfetta R, Santoni A. NK cells and interferons. Cytokine Growth Factor Rev 2015; 26(2):113-20; PMID:25443799; http://dx.doi.org/10.1016/j.cytogfr.2014.11.003
9. Rizza P, Moretti F, Capone I, Belardelli F. Role of type I interferon in inducing a protective immune response:perspectives for clinical applications. Cytokine Growth Factor Rev 2015; 26(2):195-201; PMID:25466627; http://dx.doi.org/10.1016/j.cytogfr.2014.10.002
10. Parmar S, Platanias LC. Interferons:mechanisms of action and clinical applications. Curr Opin Oncol 2003; 15(6):431-9; PMID:14624225; http://dx.doi.org/10.1097/00001622-200311000-00005
11. Gresser I. Antitumour effects of interferons:past, present and future. Br J Haematol 1991; 79 Suppl 1:1-5; PMID:1718388; http://dx.doi.org/10.1556/OH.2013.29718
12. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders:final result of a phase 2 study. Cancer 2007; 110(9):2012-8; PMID:17849460; http://dx.doi.org/10.1002/cncr.23018
13. Flisiak R, Flisiak I. Albinterferon-alpha 2b:a new treatment option for hepatitis C. Expert Opin Biol Ther 2010; 10(10):1509-15; PMID:20828335; http://dx.doi.org/10.1517/14712598.2010.521494
14. Jones TD, Hanlon M, Smith BJ, Heise CT, Nayee PD, Sanders DA, Hamilton A, Sweet C, Unitt E, Alexander G, et al. The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J Interferon Cytokine Res 2004; 24(9):560-72; PMID:15450132; http://dx.doi.org/10.1089/jir.2004.24.560
15. Xuan C, Steward KK, Timmerman JM, Morrison SL. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 2010; 115(14):2864-71; PMID:20139095; http://dx.doi.org/10.1182/blood-2009-10-250555
16. Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL. Anti-CD20-interferon-beta fusion protein therapy of murine B-cell lymphomas. J Immunother 2013; 36(5):305-18; PMID:23719241; https://doi.org/10.1097/CJI.0b013e3182993eb9
17. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007; 16(1):83-107; PMID:17155856; http://dx.doi.org/10.1517/13543784.16.1.83
18. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis:a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011; 2(12):1097-105; PMID:22866201; http://dx.doi.org/10.1177/1947601911423031
19. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011; 17(7):347-62; PMID:21481637; http://dx.doi.org/10.1016/j.molmed.2011.01.015
20. Wu WZ, Sun HC, Shen YF, Chen J, Wang L, Tang ZY, Iliakis G, Liu KD. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol 2005; 131(3):169-78; PMID:15662525; http://dx.doi.org/10.1007/s00432-004-0615-2
21. Wang J, Li G, Wang Y, Tang S, Sun X, Feng X, Li Y, Bao G, Li P, Mao X, et al. Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1alpha/VEGF secretion axis. Oncotarget 2015; 6(42):44579-92; PMID:26625311; http://dx.doi.org/10.18632/oncotarget.6373
22. Summers J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary:bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 2010; 15(1):104-11; PMID:20061402; http://dx.doi.org/10.1634/theoncologist.2009-0250
23. Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy. Clin Cancer Res 2013; 19(24):6943-56; PMID:24030704; http://dx.doi.org/10.1158/1078-0432.CCR-13-1637
24. Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, et al. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother 2011; 34(6):509-15; PMID:21654521; http://dx.doi.org/10.1097/CJI.0b013e31821dcefd
25. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma:CALGB 90206. J Clin Oncol 2008; 26(33):5422-8;PMID:18936475; http://dx.doi.org/10.1200/JCO.2008.16.9847
26. Poole RM, Vaidya A. Ramucirumab:first global approval. Drugs 2014; 74(9):1047-58; PMID:24916147; http://dx.doi.org/10.1007/s40265-014-0244-2
27. Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, et al. FDA approval summary:ramucirumab for gastric cancer. Clin Cancer Res 2015; 21(15):3372-6; PMID:26048277; http://dx.doi.org/10.1158/1078-0432.CCR-15-0600
28. Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, Lv ZQ, Gao CY, Wang BL, Zhang YM, et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 2014; 1845(2):182-201; PMID:24440852; http://dx.doi.org/10.1016/j.bbcan.2014.01.004
29. Xie W, Liu F, Wang Y, Ren X, Wang T, Chen Z, Tang M, Sun F, Li Z, Wang M, et al. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. Oncotarget 2016; 7(13):16445-61; PMID:26909862; http://dx.doi.org/10.18632/oncotarget.7501
30. Ren X, Xie W, Wang Y, Xu M, Liu F, Tang M, Li C, Wang M, Zhang J. VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells. Immunol Res 2016; 64(4):1060-70; PMID:27154226; http://dx.doi.org/10.1007/s12026-016-8800-3
31. McGuire S. World Cancer Report 2014. Geneva, Switzerland:World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016; 7(2):418-9; PMID:26980827; http://dx.doi.org/10.3945/an.116.012211
32. Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapies in the treatment of advanced colorectal cancer:a review. Ther Adv Med Oncol 2016; 8(4):276-93; PMID:27482287; http://dx.doi.org/10.1177/1758834016646734
33. Board RE, Valle JW. Metastatic colorectal cancer:current systemic treatment options. Drugs 2007; 67(13):1851-67; PMID:17722954; http://dx.doi.org/10.2165/00003495-200767130-00004
34. Deng T, Zhang L, Liu XJ, Xu JM, Bai YX, Wang Y, Han Y, Li YH, Ba Y. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study. Med Oncol 2013; 30(4):752; PMID:24174316; http://dx.doi.org/10.1007/s12032-013-0752-z
35. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26(11):1830-5; PMID:18398148; http://dx.doi.org/10.1200/JCO.2007.13.7679
36. Ban HS, Uto Y, Won M, Nakamura H. Hypoxia-inducible factor (HIF) inhibitors:a patent survey (2011-2015). Expert Opin Ther Pat 2016; 26(3):309-22; PMID:26882240; http://dx.doi.org/10.1517/13543776.2016.1146252
37. Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, Chang CH. Preclinical studies on targeted delivery of multiple IFNalpha2b to HLA-DR in diverse hematologic cancers. Blood 2011; 118(7):1877-84; PMID:21680794; http://dx.doi.org/10.1182/blood-2011-03-343145
38. Levin D, Harari D, Schreiber G. Stochastic receptor expression determines cell fate upon interferon treatment. Mol Cell Biol 2011; 31(16):3252-66; PMID:21690295; http://dx.doi.org/10.1128/MCB.05251-11
39. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma:results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2013; 31(5):573-83; PMID:23295790; http://dx.doi.org/10.1200/JCO.2012.42.7211
40. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013; 31(9):1157-63; PMID:23382472; http://dx.doi.org/10.1200/JCO.2012.44.9694
41. Steinman RM. Decisions about dendritic cells:past, present, and future. Ann Rev Immunol 2012; 30:1-22; PMID:22136168; http://dx.doi.org/10.1146/annurev-immunol-100311-102839
42. Yoo EM, Trinh KR, Tran D, Vasuthasawat A, Zhang J, Hoang B, Lichtenstein A, Morrison SL. Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma. J Interf Cytokine Res 2015; 35(4):281-91; PMID:25353626; http://dx.doi.org/10.1089/jir.2014.0125